Clinical trial
Bevacizumab in Treating Patients With Advanced Solid Tumors
NCT00416637 · Herbert Hurwitz, MD, Other · Completed
Key facts
| NCT number | NCT00416637 |
|---|---|
| Title | Bevacizumab in Treating Patients With Advanced Solid Tumors |
| Official title | Biomarker and Clinical Evaluation of Bevacizumab (Avastin) to Determine the Role of Nitric Oxide in Anti-VEGF Therapy |
| Lead sponsor | Herbert Hurwitz, MD, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | Bevacizumab (Avastin) |
| Enrollment | 27 |
| Start date | Jan 1, 2004 |
| Primary completion | Mar 1, 2006 |
| Completion | Mar 1, 2006 |
| First posted | Dec 28, 2006 |
| Last update posted | Jul 7, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: